ArticleBMC microbiology2026
Study on the correlation between respiratory microbiome alterations and disease location/severity in children with Mycoplasma pneumoniae pneumonia.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae pneumonia (MPP) is a common form of community-acquired pneumonia in children, potentially involving multiple organ systems. Accumulating evidence suggests that dysbiosis of the respiratory microbiota is associated with various respiratory diseases. Nevertheless, it remains unclear how the respiratory microbiota varies across anatomical sites, interacts with other microbes, and correlates with host immunity in children with MPP compared to non‑MPP respiratory diseases. In this study, we collected and analyzed pharyngeal swabs, sputum, and bronchoalveolar lavage fluid samples from 401 pediatric MPP patients and 287 control subjects (MPP-negative children with other respiratory conditions).Comparative analysis revealed significant respiratory microbiome dysbiosis in MPP patients, with Mycoplasmoides constituting 30.33% of the total microbial community. A discriminative model based on Mycoplasmoides abundance demonstrated excellent performance (AUC = 0.983, sensitivity = 95.3%, specificity = 98.3%). Notably, Mycoplasmoides abundance showed significant negative correlations with Prevotella, Veillonella_A, Staphylococcus, and Rothia, suggesting potential inhibitory effects.Anatomical distribution analysis indicated distinct microbial distributions: Prevotella and Veillonella_A were predominantly enriched in the upper respiratory tract, while Mycoplasmoides showed greater abundance in the lower respiratory tract. Consistency analysis supported the hypothesis of microbial translocation from upper to lower respiratory tract in affected children.Severe MPP cases exhibited significantly higher Mycoplasmoides abundance. For correlations with clinical indicators, both Mycoplasmoides and Streptococcus showed nominal associations. Our findings elucidate the complex interplay between respiratory microbiota in pediatric MPP patients and its association with disease severity and clinical outcomes. This study highlights the need for further research to explore and validate the prognostic relevance of value of these microbial markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.